Share on StockTwits

Bristol-Myers Squibb (NYSE:BMY)‘s stock had its “buy” rating reaffirmed by analysts at TheStreet in a research report issued to clients and investors on Wednesday. The analysts noted that the move was a valuation call.

Several other analysts have also recently commented on the stock. Analysts at Deutsche Bank initiated coverage on shares of Bristol-Myers Squibb in a research note on Wednesday. They set a “hold” rating and a $52.00 price target on the stock. They noted that the move was a valuation call. Separately, analysts at Jefferies Group raised their price target on shares of Bristol-Myers Squibb from $43.50 to $45.00 in a research note on Monday, August 11th. They now have a “hold” rating on the stock. Finally, analysts at Zacks reiterated a “neutral” rating on shares of Bristol-Myers Squibb in a research note on Friday, July 25th. They now have a $52.00 price target on the stock. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating and eight have given a buy rating to the stock. The stock has a consensus rating of “Hold” and an average target price of $51.83.

In other Bristol-Myers Squibb news, SVP Autenried Paul Von sold 20,000 shares of Bristol-Myers Squibb stock in a transaction that occurred on Tuesday, August 19th. The shares were sold at an average price of $49.89, for a total transaction of $997,800.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Bristol-Myers Squibb (NYSE:BMY) traded down 1.08% during mid-day trading on Wednesday, hitting $50.221. The stock had a trading volume of 2,274,675 shares. Bristol-Myers Squibb has a 1-year low of $41.32 and a 1-year high of $57.49. The stock’s 50-day moving average is $49.4 and its 200-day moving average is $50.45. The company has a market cap of $83.262 billion and a price-to-earnings ratio of 31.53.

Bristol-Myers Squibb (NYSE:BMY) last released its earnings data on Thursday, July 24th. The company reported $0.48 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.44 by $0.04. The company had revenue of $3.89 billion for the quarter, compared to the consensus estimate of $3.85 billion. During the same quarter last year, the company posted $0.44 earnings per share. Bristol-Myers Squibb’s revenue was down 3.9% compared to the same quarter last year. On average, analysts predict that Bristol-Myers Squibb will post $1.81 earnings per share for the current fiscal year.

Bristol-Myers Squibb Company (NYSE:BMY) is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products on a global basis.

Receive News & Ratings for Bristol-Myers Squibb Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Co and related companies with Analyst Ratings Network's FREE daily email newsletter.